JTC Employer Solutions Trustee Ltd Purchases Shares of 75,500 NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• JTC Employer Solutions Trustee Ltd bought a new stake in NewAmsterdam Pharma during the fourth quarter, purchasing 75,500 shares worth about $2.65 million.
• Insider selling was significant: Director Louis G. Lange and CEO Michael H. Davidson both sold large blocks of shares, and insiders sold 881,512 shares worth about $28.35 million over the last quarter.
• Analysts remain broadly bullish on NAMS, with an average rating of Moderate Buy and a consensus price target of $48, while the stock recently traded around $35.42 after a 3.1% drop.

JTC Employer Solutions Trustee Ltd purchased a new stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 75,500 shares of the company's stock, valued at approximately $2,649,000. JTC Employer Solutions Trustee Ltd owned about 0.07% of NewAmsterdam Pharma as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Capital World Investors lifted its holdings in shares of NewAmsterdam Pharma by 17.1% in the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company's stock valued at $279,358,000 after buying an additional 1,434,986 shares during the period. Wellington Management Group LLP lifted its holdings in shares of NewAmsterdam Pharma by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company's stock valued at $114,332,000 after buying an additional 697,129 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in shares of NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company's stock valued at $54,566,000 after buying an additional 1,062,359 shares during the period. Polar Capital Holdings Plc lifted its holdings in shares of NewAmsterdam Pharma by 15.6% in the 3rd quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company's stock valued at $82,807,000 after buying an additional 393,855 shares during the period. Finally, Alliancebernstein L.P. lifted its holdings in shares of NewAmsterdam Pharma by 4.0% in the 2nd quarter. Alliancebernstein L.P. now owns 2,331,583 shares of the company's stock valued at $42,225,000 after buying an additional 89,630 shares during the period. Institutional investors and hedge funds own 89.89% of the company's stock.

Insiders Place Their Bets

In related news, Director Louis G. Lange sold 44,619 shares of the company's stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $30.42, for a total value of $1,357,309.98. Following the completion of the transaction, the director owned 10,360 shares of the company's stock, valued at approximately $315,151.20. This represents a 81.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael H. Davidson sold 443,707 shares of the company's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $33.25, for a total value of $14,753,257.75. Following the completion of the transaction, the chief executive officer directly owned 174,144 shares of the company's stock, valued at $5,790,288. The trade was a 71.81% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 881,512 shares of company stock worth $28,350,236. 12.74% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on NAMS shares. Needham & Company LLC boosted their price objective on NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a "buy" rating in a report on Wednesday, February 18th. Cantor Fitzgerald reissued an "overweight" rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Wall Street Zen raised NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. Guggenheim boosted their price objective on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a "buy" rating in a report on Thursday, February 19th. Finally, HC Wainwright raised NewAmsterdam Pharma to a "strong-buy" rating in a report on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $48.00.

NewAmsterdam Pharma Trading Down 3.1%

NASDAQ NAMS opened at $35.42 on Friday. The stock has a market capitalization of $4.14 billion, a price-to-earnings ratio of -19.79 and a beta of 0.02. NewAmsterdam Pharma Company N.V. has a twelve month low of $16.95 and a twelve month high of $42.21. The stock has a 50-day moving average of $33.25 and a 200 day moving average of $34.20.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. The business had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. Equities analysts predict that NewAmsterdam Pharma Company N.V. will post -1.76 EPS for the current fiscal year.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.